Benedikt Schrage1, Daniel Burkhoff2, Nicole Rübsamen3, Peter Moritz Becher3, Michael Schwarzl1, Alexander Bernhardt4, Hanno Grahn3, Edith Lubos3, Gerold Söffker5, Peter Clemmensen3, Hermann Reichenspurner4, Stefan Blankenberg1, Dirk Westermann6. 1. Department of General and Interventional Cardiology, University Heart Center Hamburg Eppendorf, Hamburg, Germany; German Centre for Cardiovascular Research, Partner site Hamburg/Kiel/Lübeck, Hamburg, Germany. 2. Cardiovascular Research Foundation, New York, New York. 3. Department of General and Interventional Cardiology, University Heart Center Hamburg Eppendorf, Hamburg, Germany. 4. Department of Cardiovascular Surgery, University Heart Center Hamburg Eppendorf, Hamburg, Germany. 5. Department of Intensive Care Medicine, University Clinic Hamburg Eppendorf, Hamburg, Germany. 6. Department of General and Interventional Cardiology, University Heart Center Hamburg Eppendorf, Hamburg, Germany; German Centre for Cardiovascular Research, Partner site Hamburg/Kiel/Lübeck, Hamburg, Germany. Electronic address: d.westermann@uke.de.
Abstract
OBJECTIVES: This report relates the authors' ongoing experience with percutaneous left ventricular (LV) unloading by using a transaortic LV assist device in combination with venoarterial extracorporeal membrane oxygenation (VA-ECMO) and provides an in-depth analysis of the hemodynamic benefit of this approach. BACKGROUND: VA-ECMO is increasingly used in cases of severe cardiogenic shock. However, increase in afterload with subsequent LV overload is a major drawback of VA-ECMO. METHODS: Consecutive patients were treated with a transaortic LV assist device in addition to VA-ECMO for cardiogenic shock. The primary endpoint was 30-day all-cause mortality. Additional endpoints included weaning from VA-ECMO and safety endpoints. RESULTS: Between September 2013 and January 2018, 106 patients were treated with percutaneous LV unloading, using a transaortic LV assist device in combination with VA-ECMO. Successful weaning from VA-ECMO support was achieved in 51.9% of all patients. In the overall cohort, survival at day 30 was 35.8%, which was higher than predicted by the SAVE score (20%) or by the SAPS-II score (6.9%). Right heart catheterization indicated a marked decrease of PCWP after addition of the device to VA-ECMO. CONCLUSIONS: The strategy of percutaneous LV unloading using a transaortic LV assist device in combination with VA-ECMO improved outcome in an all-comers cohort compared to established risk scores. A prospective, randomized study is needed to further investigate this approach.
OBJECTIVES: This report relates the authors' ongoing experience with percutaneous left ventricular (LV) unloading by using a transaortic LV assist device in combination with venoarterial extracorporeal membrane oxygenation (VA-ECMO) and provides an in-depth analysis of the hemodynamic benefit of this approach. BACKGROUND:VA-ECMO is increasingly used in cases of severe cardiogenic shock. However, increase in afterload with subsequent LV overload is a major drawback of VA-ECMO. METHODS: Consecutive patients were treated with a transaortic LV assist device in addition to VA-ECMO for cardiogenic shock. The primary endpoint was 30-day all-cause mortality. Additional endpoints included weaning from VA-ECMO and safety endpoints. RESULTS: Between September 2013 and January 2018, 106 patients were treated with percutaneous LV unloading, using a transaortic LV assist device in combination with VA-ECMO. Successful weaning from VA-ECMO support was achieved in 51.9% of all patients. In the overall cohort, survival at day 30 was 35.8%, which was higher than predicted by the SAVE score (20%) or by the SAPS-II score (6.9%). Right heart catheterization indicated a marked decrease of PCWP after addition of the device to VA-ECMO. CONCLUSIONS: The strategy of percutaneous LV unloading using a transaortic LV assist device in combination with VA-ECMO improved outcome in an all-comers cohort compared to established risk scores. A prospective, randomized study is needed to further investigate this approach.
Authors: Maryna Masyuk; Peter Abel; Martin Hug; Bernhard Wernly; Assad Haneya; Stefan Sack; Konstantinos Sideris; Nicolas Langwieser; Tobias Graf; Georg Fuernau; Marcus Franz; Ralf Westenfeld; Malte Kelm; Stephan B Felix; Christian Jung Journal: Clin Res Cardiol Date: 2019-04-26 Impact factor: 5.460
Authors: Julien Guihaire; Francois Haddad; Mita Hoppenfeld; Myriam Amsallem; Jeffrey W Christle; Clark Owyang; Khizer Shaikh; Joe L Hsu Journal: Can J Cardiol Date: 2019-11-09 Impact factor: 5.223
Authors: Joseph E Tonna; Craig H Selzman; Saket Girotra; Angela P Presson; Ravi R Thiagarajan; Lance B Becker; Chong Zhang; Peter Rycus; Heather T Keenan Journal: JACC Cardiovasc Interv Date: 2022-01-12 Impact factor: 11.195
Authors: Enzo Lüsebrink; Leonhard Binzenhöfer; Antonia Kellnar; Christoph Müller; Clemens Scherer; Benedikt Schrage; Dominik Joskowiak; Tobias Petzold; Daniel Braun; Stefan Brunner; Sven Peterss; Jörg Hausleiter; Sebastian Zimmer; Frank Born; Dirk Westermann; Holger Thiele; Andreas Schäfer; Christian Hagl; Steffen Massberg; Martin Orban Journal: Clin Res Cardiol Date: 2022-08-20 Impact factor: 6.138
Authors: Laura M Piechura; Antonio Coppolino; Gita N Mody; Daniel E Rinewalt; Mohammed Keshk; Mitsugu Ogawa; Raghu Seethala; Erin A Bohula; David A Morrow; Steve K Singh; Hari R Mallidi; Steven P Keller Journal: J Card Surg Date: 2020-06-02 Impact factor: 1.620
Authors: Roberto Lorusso; Giuseppe Maria Raffa; Khalid Alenizy; Niels Sluijpers; Maged Makhoul; Daniel Brodie; Mike McMullan; I-Wen Wang; Paolo Meani; Graeme MacLaren; Mariusz Kowalewski; Heidi Dalton; Ryan Barbaro; Xiaotong Hou; Nicholas Cavarocchi; Yih-Sharng Chen; Ravi Thiagarajan; Peta Alexander; Bahaaldin Alsoufi; Christian A Bermudez; Ashish S Shah; Jonathan Haft; David A D'Alessandro; Udo Boeken; Glenn J R Whitman Journal: J Heart Lung Transplant Date: 2019-08-10 Impact factor: 10.247
Authors: Enzo Lüsebrink; Antonia Kellnar; Clemens Scherer; Kathrin Krieg; Mathias Orban; Tobias Petzold; Sven Peterss; Stefan Kääb; Stefan Brunner; Daniel Braun; Christian Hagl; Jörg Hausleiter; Steffen Massberg; Martin Orban Journal: Clin Res Cardiol Date: 2021-05-09 Impact factor: 5.460
Authors: Adamantios Tsangaris; Tamas Alexy; Rajat Kalra; Marinos Kosmopoulos; Andrea Elliott; Jason A Bartos; Demetris Yannopoulos Journal: Front Cardiovasc Med Date: 2021-07-07